LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Aldeyra Therapeutics Inc

Open

5.61 2.75

Overview

Share price change

24h

Current

Min

5.39

Max

5.79

Key metrics

By Trading Economics

Income

162K

-9.8M

Profit margin

-6,465.066

Employees

8

EBITDA

151K

-9.2M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+70.86% upside

Market Stats

By TradingEconomics

Market Cap

46M

351M

Previous open

2.86

Previous close

5.61

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Aldeyra Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

3 Apr 2025, 22:40 UTC

Major Market Movers

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

18 Nov 2024, 20:20 UTC

Major Market Movers

Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application

Peer Comparison

Price change

Aldeyra Therapeutics Inc Forecast

Price Target

By TipRanks

70.86% upside

12 Months Forecast

Average 9.5 USD  70.86%

High 10 USD

Low 9 USD

Based on 4 Wall Street analysts offering 12 month price targets forAldeyra Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

1.9 / 2.65Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
help-icon Live chat